Ocera Therapeutics Inc. founded in January 2005, is a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases.

Ocera’s goal is to develop safe and novel therapies that address significant unmet medical needs in the treatment of gastrointestinal and liver diseases. Ocera has assembled an executive management team with broad experience in developing and launching pharmaceutical products at both large and emerging growth companies. The company is organized to provide high efficiency in clinical development, regulatory affairs and licensing, with the goal of building a strong product pipeline, and developing compounds for accelerated commercialization of much-needed products for debilitating diseases.

Financials

Date Type Amount Investors Valuation
02/01/08 Series C 35.5M Montagu Newhall Associates, InterWest Partners, AgeChem Venture Fund, Cross Creek Capital Unknown

People

Joseph Davie (Board Member)

Linda Grais (Board Member)

Pratik Shah (Board Member)

Laurent Fischer (President/CEO)

Scott Harris (Chief Medical Officer)

View more details about all 15 people at Ocera Therapeutics

Competitors

Medigen Biotechnology: Medigen Biotechnology Corp. (hereinafter as MBC) was founded in Taiwan in 1999, focusing on the development… See Company Profile »

View more details about this company's competitors